October 05, 2012

New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population

 

New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population

Paris, France – October 5, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results from the landmark ORIGIN (Outcome Reduction with Initial Glargine INtervention) trial showing treatment with Lantus® (insulin glargine) was approximately 3-fold more likely (p<0.001) to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular (CV) risk.